Hundreds of millions of people are turning to chatbots to help figure out what's wrong with them. Doctors say that's not always a bad thing. In fact, many are using it themselves.
Targeted therapies for MASH show progress, with pegozafermin leading in efficacy for fibrosis regression and disease resolution. New research highlights the effectiveness of targeted therapies for ...
The class of anti-inflammatory drugs known as TNF-inhibitors has brought relief to many sufferers of rheumatoid arthritis, but they don't work for up to 4 of every 10 patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results